Kamoun, Walid S.
Kirpotin, Dmitri B. http://orcid.org/0000-0002-1726-4040
Huang, Zhaohua Richard http://orcid.org/0000-0002-5963-0088
Tipparaju, Suresh K. http://orcid.org/0000-0002-1085-9244
Noble, Charles O.
Hayes, Mark E. http://orcid.org/0000-0001-5230-2981
Luus, Lia http://orcid.org/0000-0003-1649-8416
Koshkaryev, Alexander
Kim, Jaeyeon http://orcid.org/0000-0003-0726-9048
Olivier, Ken
Kornaga, Tad
Oyama, Shinji
Askoxylakis, Vasileios
Pien, Christine
Kuesters, Geoffrey http://orcid.org/0000-0002-4578-115X
Dumont, Nancy http://orcid.org/0000-0002-6565-0851
Lugovskoy, Alexey A.
Schihl, Sarah A. http://orcid.org/0000-0002-5428-7671
Wilton, John H.
Geddie, Melissa L.
Suchy, James
Grabow, Stephanie
Kohli, Neeraj
Reynolds, C. Patrick
Blaydes, Rachel
Zhou, Yu http://orcid.org/0000-0002-0661-8448
Sawyer, Andrew J.
Marks, James D.
Drummond, Daryl C. http://orcid.org/0000-0001-6803-8863
Article History
Received: 28 March 2018
Accepted: 7 March 2019
First Online: 5 April 2019
Competing interests
: All of the authors affiliated with Merrimack Pharmaceuticals were employees of Merrimack Pharmaceuticals at the time of the study, with D.C.D., A.K., J.D.M., Z.R.H., A.J.S., L.L. and G.K. currently owning stock or stock options in Merrimack Pharmaceuticals.